scholarly article | Q13442814 |
P356 | DOI | 10.1080/14653240310000056 |
P953 | full work available at URL | https://api.elsevier.com/content/article/PII:S1465324903711657?httpAccept=text/plain |
https://api.elsevier.com/content/article/PII:S1465324903711657?httpAccept=text/xml | ||
P698 | PubMed publication ID | 12745589 |
P2093 | author name string | M. Nieda | |
A. J. Nicol | |||
A. Maksoud | |||
A. Tazbirkova | |||
D. C. Horley | |||
M. Okai | |||
T. M. Crough | |||
P2860 | cites work | Dendritic cells and the control of immunity | Q27860918 |
Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application | Q33536357 | ||
Dendritic cell based tumor vaccines | Q34038736 | ||
Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma | Q36375683 | ||
Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma | Q40629636 | ||
Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses | Q40848632 | ||
Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. | Q40865041 | ||
Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma | Q41044788 | ||
Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen | Q71931319 | ||
Dendritic cell-based immunotherapy for prostate cancer | Q73489469 | ||
Freezing of dendritic cells, generated from cryopreserved leukaphereses, does not influence their ability to induce antigen-specific immune responses or functionally react to maturation stimuli | Q73897603 | ||
Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells | Q74280070 | ||
Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells | Q74449986 | ||
Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides | Q74744883 | ||
Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma | Q77357197 | ||
Comparison of COBE Spectra software version 4.7 PBSC and version 6.0 auto PBSC program | Q77833904 | ||
Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma | Q78202930 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | immunology | Q101929 |
cell biology | Q7141 | ||
oncology | Q162555 | ||
immunotherapy | Q1427096 | ||
P1104 | number of pages | 9 | |
P304 | page(s) | 31-39 | |
P577 | publication date | 2003-01-01 | |
P1433 | published in | Cytotherapy | Q5201399 |
P1476 | title | Effects of leukapheresis protocol, cell processing and cryopreservation on the generation of monocyte-derived DC for immune therapy | |
P478 | volume | 5 |
Q50771098 | Monocyte enriched apheresis for preparation of dendritic cells (DC) to be used in cellular therapy. | cites work | P2860 |
Search more.